William G Herrington, Natalie Staplin, Christoph Wanner, Jennifer B Green, Sibylle J Hauske, Jonathan R Emberson, David Preiss, Parminder Judge, Kaitlin J Mayne, Sarah Y A Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K Cheung, Zhi-Hong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Cherney, Aldo P Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rossello, Katherine R Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin J Landray, Colin Baigent, Richard Haynes
BACKGROUND: The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. METHODS: We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1...
January 12, 2023: New England Journal of Medicine